In addition, AP-2α enhanced ubiquitous degradation of PD-L1 expression in several solid tumors [44], including hepatocellular carcinoma, cervical cancer, breast cancer, and mouse CT26 cells, B16F10 cells, which are commonly used in experimental tumor immunotherapy [45–47]. This evidence concerns the gene CD274 and breast cancer.